CoChat
Sign Up
Cited by 33MicroRNA in disease regulationGlioma Diagnosis and TreatmentCancer-related molecular mechanisms research

Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation

Open access
Jiang, Guli, Mu, Jing, Liu, Xing, Peng, Xiangni, Zhong, Feiya, Yuan, Wenliang, Deng, Fang, Peng, Xiaoning +2 more·2020·Scientific Reports
DOI 10.1038/s41598-020-61155-3PMC PMC7060265
Open this paper in CoChat — free accountOpen PDF

Abstract

Recent studies have highlighted the value of microRNA-21 (miR-21) as a prognostic biomarker in gliomas. However, the role of miR-21 in predicting prognosis remains controversial. We performed a comprehensive study based upon a meta-analysis and The Cancer Genome Atlas (TCGA) glioma dataset validation to clarify the prognostic significance of miR-21 in glioma patients. In this study, we searched Embase, PubMed, Web of science, CNKI, SinoMed, and Wanfang databases for records up to May 2018. Relevant data were extracted to assess the correlation between miR-21 expression and survival in glioma patients. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to describe association strength. We further used multivariate Cox regression analysis to assess miR-21 expression in the TCGA glioma dataset to validate the relationship between miR-21 expression and survival. Nine studies were included in the meta-analysis. Among them, eight studies provided data on overall survival (OS) with a pooled HR of 1.91 (95% CI: 1.34, 2.73), indicating that higher expression of miR-21 was significantly associated with worse OS in glioma patients; for the other study, which provided data on progression-free survival (PFS), no statistically significant HR was reported for PFS in the glioma patients (HR = 1.23, 95% CI: 0.41, 3.72). A multivariate Cox regression analysis of the miR-21 expression in the TCGA glioma dataset revealed that overexpression of miR-21 was a potential independent prognostic biomarker of poorer OS (HR = 1.27, 95% CI: 1.01, 1.59) and poorer PFS (HR = 1.46, 95% CI: 1.17, 1.82). Our findings suggest that higher expression of miR-21 is correlated with poorer glioma prognosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-61155-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. [1]Goodenberger ML Jenkins RB Genetics of adult glioma Cancer Genet. 2012 205 12 613 21 10.1016/j.cancergen.2012.10.009 23238284 · DOI
  2. [2]Louis DN The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 2007 114 2 97 109 10.1007/s00401-007-0278-6 17618441 PMC1929165 · DOI
  3. [3]Ostrom QT CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2008-2012 Neuro Oncol. 2015 17 Suppl 4 iv1 iv62 10.1093/neuonc/nov189 26511214 PMC4623240 · DOI
  4. [4]Ho VK Changing incidence and improved survival of gliomas Eur. J. Cancer 2014 50 13 2309 18 10.1016/j.ejca.2014.05.019 24972545 · DOI
  5. [5]Stupp R Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 2005 352 10) 987 96 10.1056/NEJMoa043330 15758009 · DOI · Paper page
  6. [6]Parsons DW An integrated genomic analysis of human glioblastoma multiforme Sci. 2008 321 5897) 1807 12 10.1126/science.1164382 PMC2820389 18772396 · DOI · Paper page
  7. [7]Niu X Prognostic factors for the survival outcome of bilateral thalamic glioma: an integrated survival analysis World Neurosurg. 2018 110 e222 e230 10.1016/j.wneu.2017.10.132 29102752 · DOI
  8. [8]Pan IW Ferguson SD Lam S Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000-2010 J. Clin. Neurosci. 2015 22 10) 1575 81 10.1016/j.jocn.2015.03.032 26122381 · DOI
  9. [9]Bartel DP MicroRNAs: target recognition and regulatory functions Cell 2009 136 2 215 33 10.1016/j.cell.2009.01.002 19167326 PMC3794896 · DOI · Paper page
  10. [10]Carthew RW Sontheimer EJ Origins and mechanisms of miRNAs and siRNAs Cell 2009 136 4 642 55 10.1016/j.cell.2009.01.035 19239886 PMC2675692 · DOI
  11. [11]Ambros V The functions of animal microRNAs Nat. 2004 431 7006 350 5 10.1038/nature02871 15372042 · DOI · Paper page
  12. [12]Gaur A Characterization of microRNA expression levels and their biological correlates in human cancer cell lines Cancer Res. 2007 67 6 2456 68 10.1158/0008-5472.CAN-06-2698 17363563 · DOI · Paper page
  13. [13]Calin GA Croce CM MicroRNA-cancer connection: the beginning of a new tale Cancer Res. 2006 66 15 7390 4 10.1158/0008-5472.CAN-06-0800 16885332 · DOI
  14. [14]Wang W Luo YP MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential J. Zhejiang Univ. Sci. B 2015 16 1 18 31 10.1631/jzus.B1400184 25559952 PMC4288941 · DOI
  15. [15]Nohata N Hanazawa T Kinoshita T Okamoto Y Seki N MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma Auris Nasus Larynx 2013 40 2 143 9 10.1016/j.anl.2012.07.001 22831895 · DOI
  16. [16]Zhang XX Cheng J Fu L Li QS Overexpression of tissue microRNA10b may help predict glioma prognosis J. Clin. Neurosci. 2016 29 59 63 10.1016/j.jocn.2015.10.046 26988656 · DOI
  17. [17]Zhang C High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma J. Transl. Med. 2012 10 119 10.1186/1479-5876-10-119 22681957 PMC3403924 · DOI
  18. [18]Lakomy R MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients Cancer Sci. 2011 102 12 2186 90 10.1111/j.1349-7006.2011.02092.x 21895872 PMC11158343 · DOI
  19. [19]Piwecka M Comprehensive analysis of microRNA expression profile in malignant glioma tissues Mol. Oncol. 2015 9 7 1324 40 10.1016/j.molonc.2015.03.007 25864039 PMC5528820 · DOI · Paper page
  20. [20]Wang WY MiR-21 expression predicts prognosis in hepatocellular carcinoma Clin. Res. Hepatol. Gastroenterol. 2014 38 6 715 9 10.1016/j.clinre.2014.07.001 25150373 · DOI
  21. [21]Li B MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer 2014 83 2 146 53 10.1016/j.lungcan.2013.11.003 24331411 · DOI
  22. [22]Liu XG High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer Med. Oncol. 2012 29 2 618 26 10.1007/s12032-011-9923-y 21516486 · DOI
  23. [23]Shi R Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients Oncotarget 2015 6 29 26971 81 10.18632/oncotarget.4699 26284486 PMC4694967 · DOI
  24. [25]Zhi F The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma Eur. J. Cancer 2010 46 9 1640 9 10.1016/j.ejca.2010.02.003 20219352 · DOI
  25. [26]Barbano R A miRNA signature for defining aggressive phenotype and prognosis in gliomas PLoS One 2014 9 10 e108950 10.1371/journal.pone.0108950 25279461 PMC4184816 · DOI
  26. [27]Qu K Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations Oncotarget 2016 7 23 33994 4010 10.18632/oncotarget.9188 27166186 PMC5085133 · DOI
  27. [29]Hermansen SK Dahlrot RH Nielsen BS Hansen S Kristensen BW MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas J. Neurooncol 2013 111 1 71 81 10.1007/s11060-012-0992-3 23104517 · DOI
  28. [30]Sathyan P Mir-21-Sox2 axis delineates glioblastoma subtypes with prognostic impact J. Neurosci. 2015 35 45 15097 112 10.1523/JNEUROSCI.1265-15.2015 26558781 PMC4642241 · DOI
  29. [31]Ilhan-Mutlu A Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens J. Neurooncol 2013 112 3 347 54 10.1007/s11060-013-1078-6 23420397 · DOI
  30. [32]Lei YY The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature World J. Surg. Oncol. 2017 15 1 68 10.1186/s12957-017-1132-5 28327158 PMC5359900 · DOI
  31. [33]Li Z Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis Onco Targets Ther. 2017 10 859 70 10.2147/OTT.S124733 28243121 PMC5317305 · DOI
  32. [34]Pan, F., Mao, H., Deng, L., Li, G. & Geng, P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol7 (9), 5622–33, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203174/ (2014). PMC4203174 25337203
  33. [35]Li C Prognostic role of microRNA-21 expression in gliomas: a meta-analysis J. Neurooncol 2016 130 1 11 7 10.1007/s11060-016-2233-7 27531352 · DOI
  34. [36]Liu X Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer Int. J. Cancer 2017 141 10 2093 102 10.1002/ijc.30895 28722210 · DOI
  35. [37]Wang N A serum exosomal microRNA panel as a potential biomarker test for gastric cancer Biochem. Biophys. Res. Commun. 2017 493 3 1322 8 10.1016/j.bbrc.2017.10.003 28986250 · DOI
  36. [38]Marques TM MicroRNAs in cerebrospinal fluid as potential biomarkers for parkinson’s disease and multiple system atrophy Mol. Neurobiol. 2017 54 10 7736 45 10.1007/s12035-016-0253-0 27844283 PMC5684261 · DOI · Paper page
  37. [39]Akers JC A cerebrospinal fluid microRNA signature as biomarker for glioblastoma Oncotarget 2017 8 40 68769 79 10.18632/oncotarget.18332 28978155 PMC5620295 · DOI
  38. [40]Song J Potential value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers for diseases Front. Immunol. 2017 8 56 10.3389/fimmu.2017.00056 28261196 PMC5311065 · DOI
  39. [41]Zuberi M Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer PLoS One 2016 11 4 e0153902 10.1371/journal.pone.0153902 27092777 PMC4836713 · DOI
  40. [42]Qiu S Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients J. Transl. Med. 2013 11 10 10.1186/1479-5876-11-10 23302469 PMC3551827 · DOI
  41. [43]Lee JA Lee HY Lee ES Kim I Bae JW Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast J. Breast Cancer 2011 14 4 269 75 10.4048/jbc.2011.14.4.269 22323912 PMC3268922 · DOI
  42. [44]Wang G Wang JJ Tang HM To SS Targeting strategies on miRNA-21 and PDCD4 for glioblastoma Arch. Biochem. Biophys. 2015 580 64 74 10.1016/j.abb.2015.07.001 26142886 · DOI
  43. [45]Wang J Li Y Wang X Jiang C Ursolic acid inhibits proliferation and induces apoptosis in human glioblastoma cell lines U251 by suppressing TGF-beta 1/miR-21/PDCD4 pathway Basic. Clin. Pharmacol. Toxicol. 2012 111 2 106 12 10.1111/j.1742-7843.2012.00870.x 22353043 · DOI
  44. [46]Zhou X Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status Lab. Invest. 2010 90 2 144 55 10.1038/labinvest.2009.126 20048743 · DOI
  45. [47]Gwak HS Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines PLoS One 2012 7 10 e47449 10.1371/journal.pone.0047449 23077620 PMC3471817 · DOI
  46. [48]Ma X Choudhury SN Hua X Dai Z Li Y Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway Carcinogenesis 2013 34 6 1216 23 10.1093/carcin/bgt044 23385064 PMC3670255 · DOI
  47. [50]Stang A Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur. J. Epidemiol. 2010 25 9 603 5 10.1007/s10654-010-9491-z 20652370 · DOI · Paper page
  48. [51]Tierney JF Stewart LA Ghersi D Burdett S Sydes MR Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 8 16 10.1186/1745-6215-8-16 17555582 PMC1920534 · DOI · Paper page
  49. [52]Parmar Mahesh K. B. Torri Valter Stewart Lesley Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Statistics in Medicine 1998 17 24 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 9921604 · DOI

Cited by

Sorted by citations

Authors
Jiang, G., Mu, J., Liu, X., Peng, X., Zhong, F., Yuan, W., Deng, F., Peng, X., Peng, S., & Zeng, X.
Affiliations
  • Central South University (CN)
  • Jishou University (CN)
  • Wuhan University (CN)
  • Shanghai Ocean University (CN)
Corresponding author
  • Peng, Xiangni
  • Peng, Sihua
  • Zeng, Xiaomin
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2020-03-06
Volume
10
Issue
1
Pages
4220-4220
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-020-61155-3
PMC
PMC7060265
OpenAlex
W3009255790
Cited by
33
References
1
Citations by year
2026: 5 · 2025: 5 · 2024: 10 · 2023: 4 · 2022: 5 · 2021: 3 · 2020: 1
FWCI
0.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
The National Natural Science Foundation of China
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
miR-21, glioma, prognostic factors, microRNA, overall survival, progression-free survival, microRNA overexpression
MeSH terms
Brain Neoplasms, Glioma, Humans, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Rate, MicroRNAs, Validation Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review